Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Langdahl BL, et al. Among authors: crittenden db. Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26. Lancet. 2017. PMID: 28755782
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Cosman F, et al. Among authors: crittenden db. N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18. N Engl J Med. 2016. PMID: 27641143 Free article. Clinical Trial.
Romosozumab Treatment in Postmenopausal Osteoporosis.
Cosman F, Crittenden DB, Grauer A. Cosman F, et al. Among authors: crittenden db. N Engl J Med. 2017 Jan 26;376(4):396-7. doi: 10.1056/NEJMc1615367. N Engl J Med. 2017. PMID: 28121504 No abstract available.
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J. Miyauchi A, et al. Among authors: crittenden db. Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z. Arch Osteoporos. 2019. PMID: 31168657 Free PMC article. Clinical Trial.
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. Cosman F, et al. Among authors: crittenden db. J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17. J Bone Miner Res. 2018. PMID: 29573473 Free article. Clinical Trial.
Unmasking romosozumab: response to commentsby Uzoigwe et al.
Cosman F, Crittenden DB, Libanati C. Cosman F, et al. Among authors: crittenden db. Osteoporos Int. 2017 Jun;28(6):2021-2022. doi: 10.1007/s00198-017-3959-6. Epub 2017 Feb 17. Osteoporos Int. 2017. PMID: 28213618 No abstract available.
34 results